scholarly journals Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

2018 ◽  
Vol 20 (9) ◽  
pp. 2210-2219 ◽  
Author(s):  
Bo Ahrén ◽  
Stephen L. Atkin ◽  
Guillaume Charpentier ◽  
Mark L. Warren ◽  
John P. H. Wilding ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Adverse Events ◽  
Gastrointestinal Adverse Events ◽  
Baseline Bmi

651-P: Higher Doses of Dulaglutide Induce Weight Loss in Patients with Type 2 Diabetes (T2D) Regardless of Baseline BMI: Post-hoc Analysis of AWARD-11

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 651-P
Author(s):  
ENZO BONORA ◽  
JUAN P. FRIAS ◽  
RALEIGH MALIK ◽  
ANITA KWAN ◽  
SOHINI RAHA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Post Hoc Analysis ◽  
Induce Weight Loss ◽  
Post Hoc ◽  
Baseline Bmi ◽  
Higher Doses

scholarly journals Effect of Gastrointestinal Adverse Events on Treatment Satisfaction in Semaglutide Treatment of Type 2 Diabetes

2017 ◽  
Vol 20 (9) ◽  
pp. A484 ◽  
Author(s):  
J Jendle ◽  
AL Birkenfeld ◽  
R Silver ◽  
K Uusinarkaus ◽  
L Højbjerre ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adverse Events ◽  
Treatment Satisfaction ◽  
Gastrointestinal Adverse Events
Sign in / Sign up

Export Citation Format

Share Document